The market has been enthusiastic about big pharma stocks like Johnson & Johnson and Pfizer so far this year. But shares of Danish drugmaker Novo Nordisk (NYSE:NVO) have only climbed a modest 6% year to date. Part of the stock's lackluster performance comes down to the Food and Drug Administration's rejection of its long-acting insulin Tresiba earlier this year. The drug has been launched in some international markets, but failing to get it on the U.S. market this year has been a blow to the company's near-term-revenue growth. Nevertheless, the stock's current valuation and long-term opportunities could be attractive to some investors. In the following video, analysts Simon Erickson and Max Macaluso discuss reasons to be optimistic about Novo Nordisk's long-term prospects.